Century Therapeutics Inc
NASDAQ:IPSC

Watchlist Manager
Century Therapeutics Inc Logo
Century Therapeutics Inc
NASDAQ:IPSC
Watchlist
Price: 1.02 USD -7.27% Market Closed
Market Cap: 86.7m USD
Have any thoughts about
Century Therapeutics Inc?
Write Note

Century Therapeutics Inc
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Century Therapeutics Inc
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
Century Therapeutics Inc
NASDAQ:IPSC
Total Liabilities & Equity
$360.7m
CAGR 3-Years
50%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Total Liabilities & Equity
$143.4B
CAGR 3-Years
-1%
CAGR 5-Years
19%
CAGR 10-Years
18%
Gilead Sciences Inc
NASDAQ:GILD
Total Liabilities & Equity
$54.5B
CAGR 3-Years
-7%
CAGR 5-Years
-2%
CAGR 10-Years
7%
Amgen Inc
NASDAQ:AMGN
Total Liabilities & Equity
$90.9B
CAGR 3-Years
12%
CAGR 5-Years
9%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Liabilities & Equity
$22.2B
CAGR 3-Years
21%
CAGR 5-Years
24%
CAGR 10-Years
25%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Liabilities & Equity
$37.4B
CAGR 3-Years
17%
CAGR 5-Years
22%
CAGR 10-Years
26%
No Stocks Found

Century Therapeutics Inc
Glance View

Market Cap
86.2m USD
Industry
Biotechnology

Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. The company is headquartered in Philadelphia, Pennsylvania and currently employs 170 full-time employees. The company went IPO on 2021-06-17. The firm is focused on developing transformative allogeneic, pluripotent stem cells (iPSC)-derived natural killer (NK) and T cell therapies to create products for the treatment of both solid tumor and hematological malignancies. Its Allo-Evasion technology is intended to prevent rejection of cell products by the host immune system, and manufacturing capabilities intended to minimize product development and supply risk. The firm's pipeline includes CNTY-101, CNTY-103, CNTY-102 and CNTY-104. The Company’s lead product candidate, CNTY-101, is focused on targeting B-cell lymphoma. CNTY-103 is designed to treat glioblastoma. CNTY-102 is designed to improve B-cell malignancy treatment. CNTY-104, is being developed to treat acute myeloid leukemia (AML). CAR design is a component of cell therapy product candidates. In addition to its programs, the Company is also actively engaged in a number of earlier stage discovery programs.

IPSC Intrinsic Value
0.37 USD
Overvaluation 64%
Intrinsic Value
Price

See Also

What is Century Therapeutics Inc's Total Liabilities & Equity?
Total Liabilities & Equity
360.7m USD

Based on the financial report for Dec 31, 2023, Century Therapeutics Inc's Total Liabilities & Equity amounts to 360.7m USD.

What is Century Therapeutics Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 3Y
50%

Over the last year, the Total Liabilities & Equity growth was -26%. The average annual Total Liabilities & Equity growth rates for Century Therapeutics Inc have been 50% over the past three years .

Back to Top